Cullinan Therapeutics, Inc.CGEMNASDAQ
LOADING
|||
Cash Flow Under Pressure
Below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-145.30M
↓ 97% below average
Average (6y)
$-73.73M
Historical baseline
Range
High:$-13.81M
Low:$-145.30M
CAGR
+48.0%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-145.30M | -8.0% |
| 2023 | $-134.48M | -5.2% |
| 2022 | $-127.80M | -190.3% |
| 2021 | $-44.02M | -47.8% |
| 2020 | $-29.78M | -42.4% |
| 2019 | $-20.92M | -51.5% |
| 2018 | $-13.81M | - |